TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02723760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-3PRGD2
Description: SPECT/CT scanning: single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on rheumatoid arthritis patients, whole-body planar and lesions section for determination the accumulation of 99mTc-3PRGD2 in the joints and other parts of the body.~For diagnosis study, each patient will be carried out SPECT/CT scanning once. For efficacy evaluation study, each patient will be carried out SPECT/CT scanning three times (before treatment, the midterm treatment and late stage treatment).
Study: NCT02072850

Intervention type: DEVICE
Intervention: Coronary pressure wire
Description: Guidewire-based coronary pressure- and temperature recordings (coronary thermodilution) with and without hyperaemia induced by intravenous administration of adenosine (140 ug/kg/min) in patients with acute ST-elevation myocardial infarction treated by emergency PCI.

Intervention type: OTHER
Intervention: Magnetic resonance imaging of the heart
Description: Cardiac magnetic resonance imaging (MRI) with gadolinium contrast imaging at baseline (\~ day 2) and 6 months (all participants) and in 30 subjects at 4 time-points (\< 12 hours, days 2, 7-10 and at 6 months).
Study: NCT01122966

Intervention type: DRUG
Group type: OTHER
Intervention: intraocular injections of bevacizumab
Description: intracameral and subconjunctival injections
Study: NCT02384603

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global postural reeducation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Segmental muscle stretching exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy
Study: NCT04783129

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education program based on 10 monthly lectures
Description: The education program consist of 10 lectures on the management of motor and non-motor alterations associate with PD will be offered by a nurse, physiotherapist, occupational therapist, speech therapist, neurologist, lawyer, nutritionist, and psychologist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education program based on 10 monthly lectures
Description: The education program consist of 10 lectures on the management of motor and non-motor alterations associate with PD will be offered by a nurse, physiotherapist, occupational therapist, speech therapist, neurologist, lawyer, nutritionist, and psychologist.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No intervention
Description: Participants will follow no education program (lecture) and will be instructed to follow their usual routine for the treatment of the disease
Study: NCT01049659

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuropsychological test
Description: Bayley test (version III) which provides several scales of development. Children are assessed just one time at two year old
Study: NCT04668131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate eye drops
Description: eye drops, three times a day
Study: NCT02095184

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: 1 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: 1 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: 1 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: 2.5 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: 2.5 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: 2.5 mg daily
Study: NCT01974050

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Text message surveillance
Study: NCT04391010

Intervention type: OTHER
Group type: OTHER
Intervention: Surgical masks
Description: Surgical masks will be applied in health care providers

Intervention type: OTHER
Group type: OTHER
Intervention: Surgical masks
Description: Surgical masks will be applied in health care providers

Intervention type: OTHER
Group type: OTHER
Intervention: Filtering respirators
Description: Filtering respirators will be applied in health care providers

Intervention type: OTHER
Group type: OTHER
Intervention: Filtering respirators
Description: Filtering respirators will be applied in health care providers
Study: NCT01935011

Intervention type: OTHER
Intervention: PD, DBS
Description: PD DBS frequency on swallowing function
Study: NCT00285935

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Clinical Care with an SSRI
Description: Participants who enroll in this phase are treated with an FDA-approved SSRI in an open-label treatment-as-usual manner, in accordance with clinical practices and at a titration rate no more rapid than the manufacturer's recommendations. The duration of the treatment phase is 8 weeks.~Other Name: fluoxetine (Prozac®), Sertraline (Zoloft®), citalopram (Celexa®), escitalopram (Lexapro®)
Study: NCT03968952

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMARThealth Pregnancy
Description: Education and Training package on high-risk pregnancies and the associated long-term cardiometabolic risks; An mHealth platform providing mobile decision support to Community Health Workers.
Study: NCT03877393

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation + gluten-free diet
Description: The probiotic and gluten-free diet group (PRO-GFD) will receive one capsule containing the probiotic mixture powder (Sanprobi Stress; Sanprobi sp. z o.o., sp.k., Szczecin, Poland) in the amount of 3 × 10\^9 colony forming units (CFU) per day divided in two equal doses, comprising two bacteria strains: Lactobacillus helveticusRosell®-52, Bifidobacterium longumRosell®-175, and excipients: potato starch, magnesium stearate, and the capsule shell of hydroxypropyl methylcellulose. The participants will be asked to consume supplements before breakfast. The group will follow the elimination diet containing no gluten.
Study: NCT04668131

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: three times a week
Study: NCT03332212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: 12 weeks
Study: NCT03877393

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplementation + gluten-free diet
Description: The placebo and gluten-free diet group (PLA-GFD) will receive one capsule containing only the excipients, i.e. maize starch, maltodextrins, and the capsule shell. The participants will be asked to consume supplements before breakfast. The group will follow the elimination diet containing no gluten.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation + gluten-containing diet
Description: The probiotic and gluten-containing diet group (PRO-GD) will receive one capsule containing the probiotic mixture powder (Sanprobi Stress; Sanprobi sp. z o.o., sp.k., Szczecin, Poland) in the amount of 3 × 10\^9 colony forming units (CFU) per day divided in two equal doses comprising two bacteria strains: Lactobacillus helveticusRosell®-52, Bifidobacterium longumRosell®-175 and excipients: potato starch, magnesium stearate, and the capsule shell of hydroxypropyl methylcellulose. The participants will be asked to consume supplements before breakfast. The group will stay with their current diet.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplementation + gluten-containing diet
Description: The placebo and gluten-containing diet group (PLA-GD) will receive one capsule containing only the excipients, i.e. maize starch, maltodextrins, and the capsule shell. The participants will be asked to consume supplements before breakfast. The group will stay with their current diet.
Study: NCT03231384

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: In this study, the remote ischemic conditioning treatment was composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which was induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation.~Doctormate, IPC-906
Study: NCT03351049

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LAL
Description: Reactive support surface with a low air loss feature

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-LAL
Description: Reactive support surface without a low air loss feature
Study: NCT00841126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium iron hydroxycarbonate
Description: 500 mg tablets, administered orally: initial dosage 500 or 1000 mg (total daily dose 1500 or 3000 mg) depending on serum phosphate concentration, titrated to a maximum DAILY dose of 9000 mg). The total daily dose should be divided and taken with meals. Any SINGLE dose should not exceed 3000 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanthanum carbonate
Description: 750 mg chewable tablets, administered orally: initial dosage 750 mg up to 3-times daily (total daily dose 2250 mg), titrated to a maximum SINGLE dose of 1500 mg (DAILY dose 3750 mg). The total daily dose should be divided and taken with meals.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg (500 mg-size) tablets, administered orally: The total daily dose should be divided and taken with meals. Any SINGLE dose should not exceed 6 tablets.
Study: NCT04382612

Intervention type: DEVICE
Group type: OTHER
Intervention: HARPOON Beating Heart Mitral Valve Repair System (MVRS)
Description: Repair of the chordae tendinae in the mitral valve.
Study: NCT02358824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828
Description: Telmisartan 80mg /S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily~(1arm:2period and 4period, 2arm:1period and 3period)
Study: NCT03332212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 12 Weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 12 Weeks
Study: NCT01658215

Intervention type: DRUG
Group type: OTHER
Intervention: V0116 transdermal patch (Test treatment )

Intervention type: DRUG
Group type: OTHER
Intervention: V0116 transdermal patch (Test treatment )

Intervention type: DRUG
Group type: OTHER
Intervention: Nicotine transdermal patch (Reference treatment )

Intervention type: DRUG
Group type: OTHER
Intervention: Nicotine transdermal patch (Reference treatment )
Study: NCT02334839

Intervention type: OTHER
Intervention: Observational only
Description: Endothelial function will be assessed using ENDO-PAT (Itamar medical LTD, Caesarea, Israel) device, which evaluates the change in peripheral vascular tone in reaction to temporal ischemia in a process called Reactive Hyperemia (RH) .The RH-PAT is a blood pressure measurement-like cuff which is placed on the non-dominant arm. A pneumatic probe is placed on the index finger bilaterally (one serves as a control). After a baseline assessment for a 5 minutes period, the cuff is inflated to a 60mm Hg pressure above the systolic pressure in order to occlude the arterial flow distal to the brachial artery. After 5 minutes of occlusion, a prompt deflation of the cuff results in a RH response and vasodilatation in the distal arteries including those monitored in the index finger. The sensor translates the change in vascular tone and the ENDO-PAT V3.0.4 device analyzes the data automatically. The results are given in a RH index scale that reflects the level of reactive hyperemia.

Intervention type: OTHER
Intervention: Observational only
Description: Endothelial function will be assessed using ENDO-PAT (Itamar medical LTD, Caesarea, Israel) device, which evaluates the change in peripheral vascular tone in reaction to temporal ischemia in a process called Reactive Hyperemia (RH) .The RH-PAT is a blood pressure measurement-like cuff which is placed on the non-dominant arm. A pneumatic probe is placed on the index finger bilaterally (one serves as a control). After a baseline assessment for a 5 minutes period, the cuff is inflated to a 60mm Hg pressure above the systolic pressure in order to occlude the arterial flow distal to the brachial artery. After 5 minutes of occlusion, a prompt deflation of the cuff results in a RH response and vasodilatation in the distal arteries including those monitored in the index finger. The sensor translates the change in vascular tone and the ENDO-PAT V3.0.4 device analyzes the data automatically. The results are given in a RH index scale that reflects the level of reactive hyperemia.

Intervention type: OTHER
Intervention: Observational only
Description: Endothelial function will be assessed using ENDO-PAT (Itamar medical LTD, Caesarea, Israel) device, which evaluates the change in peripheral vascular tone in reaction to temporal ischemia in a process called Reactive Hyperemia (RH) .The RH-PAT is a blood pressure measurement-like cuff which is placed on the non-dominant arm. A pneumatic probe is placed on the index finger bilaterally (one serves as a control). After a baseline assessment for a 5 minutes period, the cuff is inflated to a 60mm Hg pressure above the systolic pressure in order to occlude the arterial flow distal to the brachial artery. After 5 minutes of occlusion, a prompt deflation of the cuff results in a RH response and vasodilatation in the distal arteries including those monitored in the index finger. The sensor translates the change in vascular tone and the ENDO-PAT V3.0.4 device analyzes the data automatically. The results are given in a RH index scale that reflects the level of reactive hyperemia.
Study: NCT00975338

Intervention type: OTHER
Intervention: LIFEspan
Description: Rehabilitation services provided by an inter-disciplinary team of health professionals addressing the transfer of care to adult services and emerging needs related to transition to adulthood. LIFEspan staff are cross-appointed to both a pediatric and an adult hospital through a formally linked model of care.

Intervention type: OTHER
Intervention: LIFEspan
Description: Rehabilitation services provided by an inter-disciplinary team of health professionals addressing the transfer of care to adult services and emerging needs related to transition to adulthood. LIFEspan staff are cross-appointed to both a pediatric and an adult hospital through a formally linked model of care.

Intervention type: OTHER
Intervention: LIFEspan
Description: Rehabilitation services provided by an inter-disciplinary team of health professionals addressing the transfer of care to adult services and emerging needs related to transition to adulthood. LIFEspan staff are cross-appointed to both a pediatric and an adult hospital through a formally linked model of care.

Intervention type: OTHER
Intervention: Non-LIFEspan
Description: Standard of care in the absence of a formal partnership between a pediatric and an adult hospital.

Intervention type: OTHER
Intervention: Non-LIFEspan
Description: Standard of care in the absence of a formal partnership between a pediatric and an adult hospital.
Study: NCT04225416

Intervention type: OTHER
Intervention: Questionnaire/Structured Interview
Description: No intervention

Intervention type: OTHER
Intervention: Questionnaire/Structured Interview
Description: No intervention
Study: NCT04513873

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Equipment to divert the focus of children
Description: The equipment was placed in an area where the children would be able to see easily during the blood collection process. It was turned on as soon as the children sat on to the chair where the process would take place to divert the focus of the children at the equipment.
Study: NCT00759668

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acrysof Natural ReSTOR SN60D3
Description: Bilateral implantation with the AcrySof Natural ReSTOR Intraocular Lens (IOL) SN60D3 following cataract removal.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acrysof Natural Monofocal SN60AT
Description: Bilateral implantation with the AcrySof Natural Intraocular Lens (IOL) Model SN60AT following cataract removal.
Study: NCT02473107

Intervention type: OTHER
Group type: OTHER
Intervention: Advanced caries lesions detection (no activity assessment)
Description: The diagnosis strategy will based on detection of only moderate and advanced caries lesions (ICDAS scores 3 to 6). Initial caries lesions will be considered as sound surfaces. Caries activity status will not be evaluated. Clinical decision-making will be proposed for all lesions detected, based on evidence-based protocols.

Intervention type: OTHER
Group type: OTHER
Intervention: All caries lesions detection (+activity assessment)
Description: The diagnosis strategy will based on detection of initial, moderate and advanced caries lesions (ICDAS scores 1 to 6). Caries activity status will be also evaluated. Clinical decision-making will be proposed for all active lesions detected, based on evidence-based protocols. inactive caries lesions will not be treated.
Study: NCT03313388

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Drink
Description: Beverage to be consumed

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Drink
Description: Beverage to be consumed
Study: NCT01743664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR
Description: Patients in the experimental group will undergo 10 weekly sessions of 60 minutes each with EMDR following Shapiro's protocol for traumatic events

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation
Description: The patients in the control group will undergo 10 weekly relaxation sessions that include diaphragmatic breathing, progressive muscle relaxation, visualization and rapid relaxation.
Study: NCT00637598

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Mammography and tomosynthesis imaging
Description: All subjects receive the same radiation dose associated with mammography and tomosynthesis imaging (which is comparable to mammography).
Study: NCT01261650

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham treatment
Study: NCT02163278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBPR108
Description: DBPR108 capsules in four doses beginning at 25 mg and rising to 600 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: Matching placebo capsules in four doses beginning at 25 mg and rising to 600 mg.
Study: NCT03356366

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI 3T
Description: Magnetic Resonance Imaging 3 Tesla

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI 1,5T
Description: Magnetic Resonance Imaging 1,5 Tesla

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI 7T
Description: Magnetic Resonance Imaging 7 Tesla
Study: NCT00335985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB-0998
Description: 8 mL (400 mg of GB-0998)/kg per day is intravenously administered for five successive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of GB-0998
Description: 8 mL/kg per day is intravenously administered for five successive days
Study: NCT01445236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immunosuppresion withdrawal
Description: Gradual discontinuation of all immunosuppressive drugs.
Study: NCT02358824

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Description: - Telmisartan 80mg tablet, Oral, Once Daily (Combination Therapy with S-amlodipine)~(1arm:1period and 3period, 2arm: 2period and 4period)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-amlodipine
Description: - S-amlodipine 5mg tablet, Oral, Once Daily (combination Therapy with Telmisartan)~(1arm:1period and 3period, 2arm: 2period and 4period)
Study: NCT03969771

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Description: The MBSR program was developed by the University of Massachusetts Medical School.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Description: The MBSR program was developed by the University of Massachusetts Medical School.
Study: NCT01085175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMI 1195
Description: Single bolus intravenous injection of LMI 1195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMI 1195
Description: Single bolus intravenous injection of LMI 1195
Study: NCT00882011

Intervention type: OTHER
Intervention: Latest generation chemotherapies for T-LBL + transplant
Description: 1. Standard doses of one of the following chemotherapies:~   * Holzer~  * LSA2-L2 modified~  * Stanford regimen~  * Hyper CVAD~  * Sequential treatments analogous to the ones above mentioned (e.g.: GIMEMA LAL094, others)~  * Intensive chemotherapy, ALL-type, MRD oriented (NILG-TLL Clinical Trial)~2. Autologous transplant or allogeneic transplant or mini-allogeneic transplant
Study: NCT04025814

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CaregiverAssist
Description: CaregiverAssist is a proposed dHealth tool to promote parent adherence and sustained strategy use of evidence-based parenting strategies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Parent Training (CLS Parent Group)
Description: Collaborative Life Skills (CLS) program is implemented at school sites by school mental health providers who are trained by University of California San Francisco (UCSF) project staff

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Parent Training (CLS Parent Group)
Description: Collaborative Life Skills (CLS) program is implemented at school sites by school mental health providers who are trained by University of California San Francisco (UCSF) project staff
Study: NCT02716844

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Clinical Pilates exercise were given for 6 weeks, 3 days in a week
Study: NCT01823393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Valvuloplasty is performed in a conventional manner, ie with an injection of unfractionated heparin (50 IU / kg) at the start of procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: valvuloplasty is performed without heparin (placebo injection)
Study: NCT01130740

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Osteoarthritis Intervention
Description: Primary care providers receive patient-specific osteoarthritis information and treatment recommendations two times (0 and 6 months); patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.